A Phase I/II Study of Pomalidomide and Dexamethasone With Growth Factor Support in Patients With Relapsed/Refractory Multiple Myeloma
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Pomalidomide (Primary) ; Dexamethasone; Filgrastim
- Indications Multiple myeloma
- Focus Adverse reactions
- 20 Mar 2020 Status changed from active, no longer recruiting to discontinued.
- 12 Dec 2017 Results (n=12) presented at the 59th Annual Meeting and Exposition of the American Society of Hematology
- 22 Sep 2017 Status changed from recruiting to active, no longer recruiting.